Agreement - May 10, 2024
Xbrane and STADA partner with Valorum Biologics
Xbrane Biopharma and STADA have entered into an exclusive licensing agreement with US biosimilars specialist Valorum Biologics for their ranibizumab biosimilar candidate. Valorum will pay a license fee of up to USD 45 million, plus royalties on net product sales. This fee, plus royalties paid by Valorum on net sales of the product, will be […]
New Market - April 24, 2024
AstraZeneca’s Voydeya approved in the EU as add-on treatment
Voydeya has been approved as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of […]
Agreement - April 3, 2024
Oncopeptides collaborates with Vector Pharma FZCO
The two companies have announced a collaboration to commercialize Oncopeptides’ drug Pepaxti in the Middle East and North Africa countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq. Under the terms of this exclusive agreement, Vector will distribute Pepaxti to patients in the MENA region for the treatment […]
New Market - March 4, 2024
Vicore enters license agreement with Nippon Shinyaku
Vicore Pharma has entered into an exclusive licensing agreement with Nippon Shinyaku to develop and commercialize Vicore’s drug candidate C21 in Japan. Under the terms of the agreement, Vicore will receive an upfront payment of USD 10 million and is entitled to potential development and commercial milestone payments up to a total of USD 275 […]
Business article - February 29, 2024
Center for Translational Research launches CTC Netherlands
Center for Translational Research (CTR) expands its portfolio of life science service companies through the establishment of CTC Netherlands BV. CTC Netherlands BV is CTR group’s first company outside of Sweden. The new company will operate a clinical research unit that specializes in early phase patient research and healthy volunteer studies that require invasive procedures. […]
Agreement - February 13, 2024
Sobi and Handok establish joint venture for rare disease business
The joint venture will commercialize and distribute selected Sobi medicines in South Korea. The joint venture, due for incorporation in the first half of this year, is expected to enhance the Sobi and Handok collaboration, they state. Strengthening their position in the rare disease business, Handok and Sobi aim to develop, commercialize and distribute Sobi’s […]
